candesartan has been researched along with cyclosporine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mohr, FW; Olbrich, HG; Richter, H; Richter, M; Skupin, M | 1 |
| Chopra, K; Padi, SS | 1 |
| Fusshöller, A; Grabensee, B; Grünberg, W; Hetzel, GR; Plum, J; Voiculescu, A | 1 |
| Ishikawa, A; Kawabe, K; Kitamura, T; Ohta, N; Ozono, S | 1 |
| Chen, X; Gu, Y; Liang, J; Zhou, L | 1 |
1 review(s) available for candesartan and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for candesartan and cyclosporine
| Article | Year |
|---|---|
Effects of candesartan on glomerular hemodynamics and permselectivity in patients with favorable renal allograft function.
Topics: Benzimidazoles; Biphenyl Compounds; Blood Pressure; Creatinine; Cyclosporine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Transplantation; Male; Middle Aged; Tetrazoles; Transplantation, Homologous | 2005 |
Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Creatinine; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Losartan; Male; Middle Aged; Nifedipine; Plasminogen Activator Inhibitor 1; Tetrazoles; Transplantation, Homologous | 2005 |
8 other study(ies) available for candesartan and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Do vascular compartments differ in the development of chronic rejection? AT(1) blocker candesartan versus Ace blocker enalapril in an experimental heart transplant model.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Cyclosporine; Enalapril; Graft Rejection; Heart Transplantation; Hemodynamics; Immunosuppressive Agents; Models, Animal; Preoperative Care; Rats; Rats, Inbred F344; Rats, Inbred Lew; Tetrazoles | 2001 |
Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Body Weight; Creatine; Creatinine; Cyclosporine; Drinking; Female; Immunosuppressive Agents; Kidney; Kidney Diseases; Kidney Function Tests; Lipid Peroxidation; Lipid Peroxides; Male; Oxidative Stress; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Tetrazoles; Urodynamics | 2002 |
Transport characteristics of candesartan in human intestinal Caco-2 cell line.
Topics: Angiotensin II Type 1 Receptor Blockers; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Transport, Active; Biphenyl Compounds; Caco-2 Cells; Calcium Channel Blockers; Carrier Proteins; Chromatography, High Pressure Liquid; Cyclosporine; Dose-Response Relationship, Drug; Humans; Hydrogen-Ion Concentration; Immunosuppressive Agents; Tetrazoles; Verapamil | 2009 |